RADX 6-K: SEC filing

Radiopharm Theranostics

Filed with the SEC on · accession 0001213900-26-120153

RADX filed a 6-K (foreign company report) with the SEC on Nov 16, 2026. Radiopharm Theranostics announced that interim analysis of RAD101 Phase IIb data will be presented at the SNO26 conference.

Summary of the filing

Radiopharm Theranostics announced that interim analysis of RAD101 Phase IIb data will be presented at the SNO26 conference. The announcement was published to the Australian Securities Exchange and furnished via Form 6-K.

Key details

RegistrantRadiopharm Theranostics Limited
Company secretaryAmritha Sushil

✦ Ask GOAX AI about this filing — what it means for RADX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for RADX?

Click here

Frequently asked questions

What did RADX file with the SEC on Nov 16, 2026?

RADX filed a 6-K (SEC filing). Radiopharm Theranostics announced that interim analysis of RAD101 Phase IIb data will be presented at the SNO26 conference. The announcement was published to the Australian Securities Exchange and furnished via Form 6-K.

How do I read a 6-K?

How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.

Other RADX SEC filings

Get alerts when RADX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days